HBV and pregnancy: telbivudine completely blocks vertical transmission
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
- Telbivudine (Tyzeka), whether started in early or middle pregnancy, completely blocks maternal transmission of HBV to infants.
Why this matters
- This is the first report of telbivudine use in early pregnancy.
- Study of 188 pregnant women with chronic HBV.
- 62 started telbivudine at 12 wk gestation, 61 started between 20-28 wk gestation, and 65 remained untreated.
- Telbivudine was discontinued at postpartum wk 12.
- All infants received hepatitis B immunoglobulin and HBV vaccine.
- Funding: None.
- Baseline viral load was similar among the 3 study groups (7.79±0.22, 7.75±0.19, and 7.74±0.22 log10 copies/mL; P=.373).
- Pregnancy outcomes were similar among groups.
- Early and middle-pregnancy telbivudine initiation yielded similar mean HBV DNA levels prior to delivery (0.51±1.44 and 0.4...